You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023210019
Dec 20237605
Jan 20244305
Feb 20245002
Mar 20248206
Apr 20246405
May 20248803
Jun 20248204
Jul 202413203
Aug 2024122011
Sep 202411006
Oct 2024242015
Nov 202418009
Dec 2024110011
Jan 2025125014
Feb 202536010
Mar 20250012
Apr 2025002
May 2025108
Jun 2025109
Total17540159